SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Verismo Presents Preclinical Data at SITC 2026

The company said its SynKIR™ KIR-CAR showed faster tumor control and approximately 10-fold lower IFNγ, with 30-fold lower cytokine release, than conventional CAR T.

Related stories